NCT07589530 is a Phase 1, PHASE2 clinical trial of EB-NK-301 in Advanced Solid Tumors, sponsored by Beijing Biotech.

Who is sponsoring NCT07589530?

NCT07589530 is sponsored by Beijing Biotech.

What drugs are being tested in NCT07589530?

Interventions in NCT07589530: EB-NK-301, Fludarabine.

What condition does NCT07589530 study?

NCT07589530 studies Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors.

Is NCT07589530 still recruiting?

NCT07589530 is currently recruiting now.

Last reviewed 2026-06-10 · How we verify

NCT07589530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Recruiting now Phase 1, PHASE2

What this trial tests

Phase 1, PHASE2 trial testing EB-NK-301 in Advanced Solid Tumors in 60 participants. Currently enrolling.

Timeline

2 March 2026

17 March 2028

Quick facts

Lead sponsor	Beijing Biotech
Phase	Phase 1, PHASE2
Status	Recruiting now
Enrollment	60
Start date	2 March 2026
Estimated completion	17 March 2028

Drugs / interventions tested

EB-NK-301
Fludarabine (FLUDARABINE) — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Metastatic Solid Tumors — all drugs for Metastatic Solid Tumors →
TROP2-Expressing Solid Tumors — all drugs for TROP2-Expressing Solid Tumors →

Sponsor

Beijing Biotech — full company profile →

Who can join

Eligibility, any sex, with Advanced Solid Tumors or Metastatic Solid Tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07349160 — Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Sol · EARLY_PHASE1 · recruiting

Other Beijing Biotech trials

Trials by the same sponsor.

NCT07523529 — Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07510815 — Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma · Phase 1, PHASE2 · recruiting
NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07589530 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Biotech
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07589530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing